ABIVAX Société Anonyme

The 2025 recapitalized balance sheet gives Abivax time for obefazimod’s clinical/regulatory milestones to determine value rather than forcing near-term distressed financing. If runway holds, shareholders own the clinical upside; if it fails, dilution or weak partnering terms can absorb much of the drug’s value.

Abivax’s rising operating losses are acceptable only if they are buying real clinical and regulatory de-risking for obefazimod, not merely extending development uncertainty. The owner should tolerate losses if they move the asset toward approval; the same losses destroy value if the program stalls or needs more trials.

Obefazimod must prove differentiated enough versus existing ulcerative-colitis treatment options for physicians and payers to care about a new entrant from a pre-commercial company. Approval alone may not create large value; durable upside requires a product profile strong enough to support adoption, pricing, and potential partner interest.

Per-share value creation depends on Abivax reaching a value-inflecting clinical, regulatory, or strategic outcome before repeated equity financing becomes the dominant funding mechanism. A drug can succeed clinically while common shareholders earn poor returns if ownership is repeatedly diluted before the payoff.